Discontinuation of statins in older patients with polypharmacy associated with increased cardiovascular events
1. Older patients with polypharmacy who discontinued statins had increased rates of admissions for heart failure, all-cause emergency hospital admissions, cardiovascular outcomes, and all-cause...
Postpartum mental illness increased in frequency during the COVID-19 pandemic
1. Clinical visits for postpartum mental health illness increased in the first 9 months of the COVID-19 pandemic comparatively to pre-pandemic rates, peaking between...
Annual screening for ovarian cancer does not significantly reduce mortality
1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer compared to no annual...
Chemotherapy during the first trimester of pregnancy associated with increased risk for congenital malformations...
1. Chemotherapy was associated with an increased risk of major congenital malformations in the initial 12 weeks of pregnancy.
2. These risks and the prevalence...
Caregiver-reported health-related quality of life of New Zealand children born very and extremely preterm
1. Caregivers reported good health related quality of life of New Zealand children despite their shorter gestational periods
2. Neurodevelopmental impairment and socio-economic deprivation were...
Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis
1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis (vIGA-AD) scores significantly more...
Intravenous eptinezumab associated with a more rapid onset and prolongation of symptom relief from...
1. Intravenous eptinezumab-treated participants achieved significantly earlier freedom from headaches and from their most bothersome symptoms compared to placebo in those suffering from an...
Upadacitinib monotherapy is effective for patients with moderate-to-severe atopic dermatitis
1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups than the placebo group.
2....
Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors
1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner.
2. Thrombotic biomarkers including fibrinogen, serum amyloid...
